CB2 Liver Findings Concerned Kupffer-Cell Responses, Not a General Immune Boost
A review’s CB2-related liver findings involved particular inflammatory cell responses in alcohol-exposed animal models. They do not establish that cannabinoids generally strengthen immunity or improve every immune function.
The reviewed mechanism was tissue-specific
Kunos describes experimental CB2 agonists reducing liver inflammation and steatosis alongside changes in Kupffer-cell inflammatory phenotype. Additional work linked the anti-inflammatory response with autophagy-related mechanisms.
Kupffer cells are liver macrophages. Changes in their experimental response are not equivalent to a demonstrated reduction in infections or improved whole-body immune performance.
Reduced inflammation and host defense are different outcomes
A response that reduces injury-associated inflammation may be beneficial in one setting without answering how the organism handles pathogens. The endpoint being measured determines what improvement means.
The review also describes more prominent effects of a plant-derived CB2-active compound in wild-type than receptor-deficient mice. That supports receptor involvement within the model without establishing universal specificity or a human treatment effect.
Avoid converting a mechanism into a product claim
The evidence concerns selected compounds, exposures and alcohol-related models. It cannot establish that smoking cannabis reproduces those effects or that a retail product prevents liver disease.
The useful finding is a bounded immune-cell mechanism requiring further translation. It is not a general claim of immune enhancement.
Related: Interpreting cannabis tolerance claims.
Research cited
Kunos G Alcoholism, clinical and experimental research · 2020 · 44(4):790 PMID 32056226 · DOI 10.1111/acer.14306. Interactions Between Alcohol and the Endocannabinoid System..
